Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

Christen Lykkegaard Andersen; Mads Emil Bjørn; Mary Frances McMullin; Claire Harrison; Jan Samuelsson; Elisabeth Ejerblad; Sonja Zweegman; Savio Fernandes; David Bareford; Steven Knapper; Eva Löfvenberg; Olle Linder; Bjørn Andreasson; Erik Ahlstrand; Morten Krogh Jensen; Ole Weis Bjerrum; Hanne Vestergaard; Herdis Larsen; Tobias Wirenfeldt Klausen; Torben Mourits-Andersen; Vibe Skov; Mads Thomassen; Torben Kruse; Kirsten Grønbæk; Hans Carl Hasselbalch

doi:10.1016/j.leukres.2014.04.002

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

Christen Lykkegaard Andersen^*, Mads Emil Bjørn, Mary Frances McMullin, Claire Harrison, Jan Samuelsson, Elisabeth Ejerblad, Sonja Zweegman, Savio Fernandes, David Bareford, Steven Knapper, Eva Löfvenberg, Olle Linder, Bjørn Andreasson, Erik Ahlstrand, Morten Krogh Jensen, Ole Weis Bjerrum, Hanne Vestergaard, Herdis Larsen, Tobias Wirenfeldt Klausen, Torben Mourits-AndersenVibe Skov, Mads Thomassen, Torben Kruse, Kirsten Grønbæk, Hans Carl Hasselbalch

^*Corresponding author af dette arbejde

Hæmatologisk Afdeling

Publikation: Bidrag til tidsskrift › Artikel › Forskning › peer review

Abstract

YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<. 0.0001) and 1.7 times higher than in ET (P= 0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.

Originalsprog	Engelsk
Sider (fra-til)	816-821
Antal sider	6
Tidsskrift	Leukemia Research
Vol/bind	38
Udgave nummer	7
DOI	https://doi.org/10.1016/j.leukres.2014.04.002
Status	Udgivet - jul. 2014

Adgang til dokumentet

10.1016/j.leukres.2014.04.002

Andre filer og links

http://www.scopus.com/inward/record.url?scp=84902075803&partnerID=8YFLogxK

Citationsformater

Andersen, C. L., Bjørn, M. E., McMullin, M. F., Harrison, C., Samuelsson, J., Ejerblad, E., Zweegman, S., Fernandes, S., Bareford, D., Knapper, S., Löfvenberg, E., Linder, O., Andreasson, B., Ahlstrand, E., Jensen, M. K., Bjerrum, O. W., Vestergaard, H., Larsen, H., Klausen, T. W., ... Hasselbalch, H. C. (2014). Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. Leukemia Research, 38(7), 816-821. https://doi.org/10.1016/j.leukres.2014.04.002

@article{e5d93531275547ee8259bda9f5e45c86,

title = "Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat",

abstract = "YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<. 0.0001) and 1.7 times higher than in ET (P= 0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.",

keywords = "Essential thrombocythemia, Phase II study, Polycythemia vera, Vorinostat, Ykl-40",

author = "Andersen, {Christen Lykkegaard} and Bj{\o}rn, {Mads Emil} and McMullin, {Mary Frances} and Claire Harrison and Jan Samuelsson and Elisabeth Ejerblad and Sonja Zweegman and Savio Fernandes and David Bareford and Steven Knapper and Eva L{\"o}fvenberg and Olle Linder and Bj{\o}rn Andreasson and Erik Ahlstrand and Jensen, {Morten Krogh} and Bjerrum, {Ole Weis} and Hanne Vestergaard and Herdis Larsen and Klausen, {Tobias Wirenfeldt} and Torben Mourits-Andersen and Vibe Skov and Mads Thomassen and Torben Kruse and Kirsten Gr{\o}nb{\ae}k and Hasselbalch, {Hans Carl}",

year = "2014",

month = jul,

doi = "10.1016/j.leukres.2014.04.002",

language = "English",

volume = "38",

pages = "816--821",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier",

number = "7",

}

Andersen, CL, Bjørn, ME, McMullin, MF, Harrison, C, Samuelsson, J, Ejerblad, E, Zweegman, S, Fernandes, S, Bareford, D, Knapper, S, Löfvenberg, E, Linder, O, Andreasson, B, Ahlstrand, E, Jensen, MK, Bjerrum, OW, Vestergaard, H, Larsen, H, Klausen, TW, Mourits-Andersen, T, Skov, V, Thomassen, M, Kruse, T, Grønbæk, K & Hasselbalch, HC 2014, 'Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat', Leukemia Research, bind 38, nr. 7, s. 816-821. https://doi.org/10.1016/j.leukres.2014.04.002

TY - JOUR

T1 - Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

AU - Andersen, Christen Lykkegaard

AU - Bjørn, Mads Emil

AU - McMullin, Mary Frances

AU - Harrison, Claire

AU - Samuelsson, Jan

AU - Ejerblad, Elisabeth

AU - Zweegman, Sonja

AU - Fernandes, Savio

AU - Bareford, David

AU - Knapper, Steven

AU - Löfvenberg, Eva

AU - Linder, Olle

AU - Andreasson, Bjørn

AU - Ahlstrand, Erik

AU - Jensen, Morten Krogh

AU - Bjerrum, Ole Weis

AU - Vestergaard, Hanne

AU - Larsen, Herdis

AU - Klausen, Tobias Wirenfeldt

AU - Mourits-Andersen, Torben

AU - Skov, Vibe

AU - Thomassen, Mads

AU - Kruse, Torben

AU - Grønbæk, Kirsten

AU - Hasselbalch, Hans Carl

PY - 2014/7

Y1 - 2014/7

N2 - YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<. 0.0001) and 1.7 times higher than in ET (P= 0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.

AB - YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<. 0.0001) and 1.7 times higher than in ET (P= 0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.

KW - Essential thrombocythemia

KW - Phase II study

KW - Polycythemia vera

KW - Vorinostat

KW - Ykl-40

UR - http://www.scopus.com/inward/record.url?scp=84902075803&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2014.04.002

DO - 10.1016/j.leukres.2014.04.002

M3 - Article

C2 - 24836761

AN - SCOPUS:84902075803

VL - 38

SP - 816

EP - 821

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 7

ER -

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater